SI-BONE, Inc. SIBN
SI-BONE, Inc. (SIBN) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $200.9M at a -9.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.95 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.8 |
| Retained earnings / assets | -1.887 |
| EBIT / assets | -0.094 |
| Equity / liabilities | 2.909 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SIBN | SI-BONE, Inc. | 6/9 | 1.52 | — | +20.2% |
| TMCI | TREACE MEDICAL CONCEPTS, INC. | 2/9 | -1.79 | — | +1.6% |
| HTFL | Heartflow, Inc. | 4/9 | -2.45 | — | +39.9% |
| CERS | CERUS CORP | 4/9 | -13.54 | — | +16.1% |
| KIDS | ORTHOPEDIATRICS CORP | 4/9 | 2.67 | — | +15.4% |
| LMAT | LEMAITRE VASCULAR INC | 6/9 | 8.18 | 37.9 | +13.5% |
| STIM | Neuronetics, Inc. | 4/9 | -10.38 | — | +99.2% |
About SI-BONE, Inc.
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
FAQ
Is SIBN financially healthy?
SI-BONE, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does SIBN pay a dividend?
No, SI-BONE, Inc. does not currently pay a dividend.
How profitable is SIBN?
In FY2025, SI-BONE, Inc. had a net margin of -9.4% and a return on equity of -10.6%.
What is the analyst price target for SIBN?
The average Wall-Street price target for SI-BONE, Inc. is $24.12, about 27.0% above the recent price, from 8 analysts.
Is SIBN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on SI-BONE, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.